Experimental Surgery, Research Institute-McGill University Health Centre, Montreal, QC, Canada; Department of Urology, McGill University Health Centre, McGill University, Montreal, QC, Canada.
Experimental Surgery, Research Institute-McGill University Health Centre, Montreal, QC, Canada.
Urol Oncol. 2021 May;39(5):299.e7-299.e14. doi: 10.1016/j.urolonc.2020.10.001. Epub 2020 Oct 23.
Radiation-based therapy (RT) has emerged as a suitable alternative to radical cystectomy (RC) and pelvic lymph node dissection for muscle-invasive bladder cancer (MIBC) patients. Routine biopsy after RT to rule out residual disease remains inconsistent across guidelines. Our objective was to review the significance of a bladder biopsy in terms of assessment of response post-RT and its potential impact on survival.
This was a single-center retrospective study on patients with MIBC (cT2-4aN0-2M0) treated with curative intent RT. A total of 169 patients with primary urothelial carcinoma were analyzed. Patients' demographic, clinical and pathological variables, imaging, cystoscopy, urine cytology, and biopsy reports after RT were collected and compiled. Whenever urine cytology was positive or cystoscopy showed any malignant-appearing lesion, the first assessment post-RT was considered suspicious for residual disease. A descriptive population analysis was reported. Cox regression multivariable analysis was performed to identify independent variables associated with survival outcomes.
Median age was 75 years (interquartile range 66-82) and clinical staging was cT2 in 152 (90%) patients. Cytology and cystoscopy were normal in 140 (83%) after RT. Of patients with a control biopsy, residual MIBC was present in 3 (5%) and non-MIBC in another 6 (11%). On the contrary, a for-cause biopsy due to a suspicious assessment post-RT did not yield residual cancer in 45% of patients. Multivariable analysis showed that age (hazard ratio [HR] 1.04, P< 0.001), lymphovascular invasion (HR 1.68, P = 0.03) and a suspicious assessment after RT (HR 3.21; P< 0.001) were significantly associated with worse OS. This study was limited by its retrospective design.
A routine biopsy after RT may be warranted to assess treatment response. This might be particularly important for patients who may benefit from early surgical intervention for residual MIBC. Further prospective studies are needed to confirm our findings.
对于肌层浸润性膀胱癌(MIBC)患者,放射治疗(RT)已成为根治性膀胱切除术(RC)和盆腔淋巴结清扫术的合适替代方法。RT 后常规活检以排除残留疾病在指南中仍然不一致。我们的目的是回顾评估 RT 后反应和对生存的潜在影响的膀胱活检的意义。
这是一项对接受根治性 RT 治疗的 MIBC(cT2-4aN0-2M0)患者的单中心回顾性研究。共分析了 169 例原发性尿路上皮癌患者。收集并编译了患者的人口统计学、临床和病理变量、影像学、膀胱镜检查、尿液细胞学和 RT 后活检报告。只要尿液细胞学阳性或膀胱镜检查显示任何恶性外观病变,RT 后的首次评估即被认为是可疑的残留疾病。报告了描述性的人群分析。进行了 Cox 回归多变量分析,以确定与生存结果相关的独立变量。
中位年龄为 75 岁(四分位距 66-82),临床分期为 152 例(90%)cT2。140 例(83%)患者在 RT 后细胞学和膀胱镜检查正常。在进行控制活检的患者中,3 例(5%)存在残留 MIBC,6 例(11%)存在非 MIBC。相反,由于可疑的 RT 后评估而进行的有原因活检在 45%的患者中未发现残留癌症。多变量分析显示年龄(风险比[HR] 1.04,P<0.001)、脉管侵犯(HR 1.68,P=0.03)和 RT 后可疑评估(HR 3.21;P<0.001)与 OS 更差显著相关。这项研究受到其回顾性设计的限制。
RT 后常规活检可能需要评估治疗反应。这对于可能受益于残留 MIBC 早期手术干预的患者可能尤为重要。需要进一步的前瞻性研究来证实我们的发现。